Fundraising Fox
/Companies
Sign in

Nu-Med Plus

OTC: NUMD

Salt Lake City, US · Founded 2011 · Utah corporation

Find your way into Nu-Med Plus

Sign up to see every warm intro you have to Nu-Med Plus

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Nu-Med Plus team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Nu-Med Plus develops medical devices that generate and deliver nitric oxide gas for clinical, hospital, and research applications. The company's products—including formulations, bedside delivery systems for intensive care, portable rechargeable units, and laboratory research equipment—are designed to reduce the cost and improve the accessibility of nitric oxide therapy for treating conditions including hypoxia in newborns and potentially other diseases, pending FDA approval.

Biotech

Founders & leadership

JL
Jeffrey L. RobinsExecutive
WG
William Grant MoonExecutive
BJ
Brett J. Earl, MDExecutive
CWCraig W. Morrison
Craig W. MorrisonExecutive
TT
Tom TaitExecutive
WH
William HaydeCEO, Director
KL
Keith L. MerrellChief Financial Officer, Director

Reported raises · per SEC filings

Form D private placements

$1.2M disclosed across 8 rounds · 2012–2018

▶$35KraisedDec 2018 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jeffrey L. RobinsExecutive Officer, Director
  • Brett J. Earl, MDExecutive Officer, Director
  • William Grant MoonExecutive Officer, Director
  • Keith MerrellExecutive Officer
  • Craig W. MorrisonExecutive Officer, Director
  • Tom TaitExecutive Officer, Director
Offering amount
$600K
Amount sold
$35K
Minimum investment
$10K
Proceeds to insiders
$35K
First sale
Oct 2018
Incorporated
Corporation, Utah
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$660.4KraisedSep 2017 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • William Grant MoonExecutive Officer, Director
  • Jeffrey L. RobinsExecutive Officer, Director
  • Brett J. Earl, MDExecutive Officer, Director
  • Craig W. MorrisonExecutive Officer, Director
  • Tom TaitExecutive Officer, Director
Offering amount
$700K
Amount sold
$660.4K
Minimum investment
$25K
Proceeds to insiders
$35K
First sale
Feb 2017
Incorporated
Corporation, Utah
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$45KraisedSep 2017 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • William Grant MoonExecutive Officer, Director
  • Tom TaitExecutive Officer, Director
  • Jeffrey L. RobinsExecutive Officer, Director
  • Brett J. Earl, MDExecutive Officer, Director
  • Craig W. MorrisonExecutive Officer, Director
Offering amount
$400K
Amount sold
$45K
Minimum investment
$5K
Proceeds to insiders
$36K
First sale
Sep 2017
Incorporated
Corporation, Utah
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.5KraisedAug 2015 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • William Grant MoonExecutive Officer, Director
  • Tom TaitExecutive Officer, Director
  • Brett J. Earl, MDExecutive Officer, Director
  • Jeffrey L. RobinsExecutive Officer, Director
  • Craig W. MorrisonExecutive Officer, Director
Offering amount
$30K
Amount sold
$2.5K
Minimum investment
$30K
Proceeds to insiders
$3.5K
First sale
Aug 2015
Incorporated
Corporation, Utah, 2011
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$30KraisedApr 2015 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jeffrey L. RobinsExecutive Officer, Director
  • William Grant MoonExecutive Officer, Director
  • Brett J. Earl, MDExecutive Officer, Director
  • Craig W. MorrisonExecutive Officer, Director
  • Tom TaitExecutive Officer, Director
Offering amount
$30K
Amount sold
$30K
Minimum investment
$30K
Proceeds to insiders
$7.5K
First sale
Apr 2015
Incorporated
Corporation, Utah, 2011
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$164KraisedSep 2014 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Craig W. MorrisonExecutive Officer, Director
  • Jeffrey L. RobinsExecutive Officer, Director
  • William Grant MoonExecutive Officer, Director
Offering amount
$171.5K
Amount sold
$164K
Minimum investment
$6.5K
First sale
Apr 2014
Incorporated
Corporation, Utah, 2011
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$130KraisedMay 2014 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • William Grant MoonExecutive Officer, Director
  • Craig W. MorrisonExecutive Officer, Director
  • Jeffrey L. RobinsExecutive Officer, Director
Offering amount
$130K
Amount sold
$130K
Minimum investment
$50K
First sale
Oct 2013
Incorporated
Corporation, Utah, 2011
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$87.7KraisedMar 2012 · 55 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Craig W. MorrisonExecutive Officer, Director
  • Jeffrey L. RobinsExecutive Officer, Director
  • William Grant MoonExecutive Officer, Director
Offering amount
$125K
Amount sold
$87.7K
Minimum investment
$100
Proceeds to insiders
$25K
First sale
Mar 2012
Incorporated
Corporation, Utah, 2011
Federal exemptions
06
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Nu-Med Plus do?
Nu-Med Plus develops medical devices that generate and deliver nitric oxide gas for clinical, hospital, and research applications. The company's products—including formulations, bedside delivery systems for intensive care, portable rechargeable units, and laboratory research equipment—are designed to reduce the cost and improve the accessibility of nitric oxide therapy for treating conditions including hypoxia in newborns and potentially other diseases, pending FDA approval.
How much funding has Nu-Med Plus raised?
Nu-Med Plus has disclosed $1.2M raised across 8 rounds.
Where is Nu-Med Plus headquartered?
Nu-Med Plus is headquartered in Salt Lake City, US.